A comprehensive characterization of chronic norovirus infection in immunodeficient hosts

J Allergy Clin Immunol. 2019 Nov;144(5):1450-1453. doi: 10.1016/j.jaci.2019.07.036. Epub 2019 Aug 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD19 / metabolism
  • Antiviral Agents / therapeutic use
  • B-Lymphocytes / immunology*
  • Caliciviridae Infections / diagnosis
  • Caliciviridae Infections / drug therapy
  • Caliciviridae Infections / immunology*
  • Cells, Cultured
  • Common Variable Immunodeficiency / diagnosis
  • Common Variable Immunodeficiency / drug therapy
  • Common Variable Immunodeficiency / immunology*
  • Enterocolitis
  • Female
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Nitro Compounds
  • Norovirus / physiology*
  • Programmed Cell Death 1 Receptor / metabolism
  • Recurrence
  • Ribavirin / therapeutic use
  • Species Specificity
  • T-Lymphocytes / immunology*
  • Thiazoles / therapeutic use
  • Treatment Outcome
  • Up-Regulation

Substances

  • Antigens, CD19
  • Antiviral Agents
  • Nitro Compounds
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Thiazoles
  • Ribavirin
  • nitazoxanide